Hostname: page-component-8448b6f56d-c4f8m Total loading time: 0 Render date: 2024-04-25T06:28:57.770Z Has data issue: false hasContentIssue false
  • English
  • Français

Sulpiride and Haloperidol in Schizophrenia: A Double-blind Cross-over Study of Therapeutic Effect, Side Effects and Plasma Concentrations

Published online by Cambridge University Press:  29 January 2018

Jes Gerlach ,
Kirsten Behnke ,
Jon Heltberg ,
Ebbe Munk-Andersen  and
Henrik Nielsen
Jes Gerlach*
Affiliation:
Sct. Hans Hospital, Dept. AEH, 4000 Roskilde, Denmark
Kirsten Behnke
Affiliation:
Sct. Hans Hospital, Dept. AEH, 4000 Roskilde, Denmark
Jon Heltberg
Affiliation:
Sct. Hans Hospital, Dept. AEH, 4000 Roskilde, Denmark
Ebbe Munk-Andersen
Affiliation:
Sct. Hans Hospital, Dept. AEH, 4000 Roskilde, Denmark
Henrik Nielsen
Affiliation:
Sct. Hans Hospital, Dept. AEH, 4000 Roskilde, Denmark
*
∗Correspondence
Get access Rights & Permissions [Opens in a new window]

Summary

In a double-blind cross-over trial, 20 chronic schizophrenic patients were treated with sulpiride and haloperidol in two 12-week periods. The final median dose of sulpiride was 2000 mg/day (range 800–3200) and of haloperidol 12 mg/day (range 6–24). Sulpiride had an antipsychotic effect and therapeutic profile not significantly different from that of haloperidol. In spite of the high doses of sulpiride, extrapyramidal side-effects were seen less frequently during the first four weeks of the sulpiride period than during the corresponding haloperidol period (P < 0.05), whereas autonomic side-effects were equally rare for both drugs. A positive correlation was found between daily dose and plasma concentration of both sulpiride (P < 0.001) and haloperidol (P < 0.05), but no correlation could be established between clinical effects and plasma levels of either neuroleptic.

Type
Papers
Information
The British Journal of Psychiatry , Volume 147 , Issue 3 , September 1985 , pp. 283 - 288
Copyright
Copyright © 1985 The Royal College of Psychiatrists 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Brattos, O. & Haug, J. O. (1979) Comparison of sulpiride and chlorpromazine in psychoses. Acta Psychiatrica Scandinavica, 135, 164–173.Google Scholar
Cardoso, M. T. & Pradelles, P. (1982) Preparation of N(lethyl 2 pyrrolidyl methyl) 2 methoxy 4 iodo 125I 5 ethyl sulfonyl benzamide: a radioligand for the radioimmunoassay of sulpiride-related compounds. Journal of Labelled Compounds and Radiopharmaceuticals, 19, 1103–1109.CrossRefGoogle Scholar
Cassano, G. B., Castrogiovanni, P., Conti, L. & Bonollo, L. (1975) Sulpiride versus haloperidol in schizophrenia: A double-blind comparative trial. Current Therapeutic Research, 17, 189–201.Google ScholarPubMed
Davis, J. M., Hendricks, K. & Javaid, J. I. (1982) Antipsychotics and clinical response: An overview. Psychopharmacology Bulletin, 18, 225–227.Google Scholar
Edwards, J. G., Alexander, J. R., Alexander, M. S., Gordon, A. & Zutchi, T. (1980) Controlled trial of sulpiride in chronic schizophrenic patients. British Journal of Psychiatry, 137, 522–529.CrossRefGoogle ScholarPubMed
Elizur, A. & Davidson, S. (1975) The evaluation of the anti-autistic activity of sulpiride. Current Therapeutic Research, 18, 578–584.Google Scholar
Feighner, J. P., Robins, E., Guze, S. B., Woodruff, R. A., Winokur, G. & Munoz, R. (1972) Diagnostic criteria for use in psychiatric research. Archives of General Psychiatry, 26, 57–63.CrossRefGoogle ScholarPubMed
Fuxe, K., Ogren, S. O., Hall, H., Agnati, L. F., Andersson, K., Kohler, C. & Schwartz, R. (1980) Effects of chronic treatment with l-sulpiride and haloperidol on central manoaminergic mechanisms In Long-term Effects of Neuroleptics (eds. Cattabeni, et al.) New York: Raven Press.Google Scholar
Gerlach, J. & Korsgaard, S. (1981) Classification and prevalence of neuroleptic-induced hyperkinetic disorders In Biological Psychiatry (eds. Perris, C., Struwe, G. and Jansson, B.). Amsterdam: Elsevier, North-Holland Biomedical Press.Google Scholar
Gerlach, J. & Casey, D. (1984) Sulpiride in tardive dyskinesia. Acta Psychiatrica Scandinavica, suppl. No. 311, 69, 93–102.CrossRefGoogle Scholar
Hagström, J. E. (1984) Effect of sulpiride on persistent neuroleptic-induced dyskinesia in monkeys. Acta Psychiatrica Scandinavica, Suppl. 311, 69, 103–108.CrossRefGoogle Scholar
Härnryd, C., Bjerkenstedt, L., Bjork, K., Gullberg, B., Oxenstierna, G., Sedvall, G., Wiesel, F. A., Wik, C. & Åberg-Wistedt, A. (1984) Clinical evaluation of sulpiride in schizophrenic palients—A double-blind comparison with chlorpromazine. Acta Psychiatrica Scandinavica, Suppl. 311, 69, 7–30.CrossRefGoogle Scholar
Ishimaru, T., Kubo, S., Ishikawa, H., Jitsuiki, S., Kawamura, T., Kimura, N., Kodama, H., Masuda, K., Miyake, Y., Nomura, S., Sasaki, T., Schimonaga, K., Tsukue, I. & Asada, S. (1971) Clinical evaluation on therapeutic effects of sulpiride, a neuroleptic drug, on schizophrenia by double-blind controlled test. Hiroshima Journal of Medical Science, 19, 131–154.Google Scholar
Jenner, P. & Marsden, D. D. (1981) Substituted benzamide drugs as selective neuroleptic agents. Neuropharmacology, 20, 1,285–1,293.Google ScholarPubMed
Jenner, P. Hall, M. D., Murugaiah, K., Rupniak, N., Theodorou, A. & Marsden, C. D. (1982) Repeated administration of sulpiride for three weeks produces behavioural and biochemical evidence for cerebral dopamine receptor supersensitivity. Biochemical Pharmacology, 31, 325–328.CrossRefGoogle ScholarPubMed
Köhler, C., Haglund, L., Ögren, S.-O. & Ängeby, T. (1981) Regional blockade by neuroleptic drugs of in vivo 3H-spiperone binding in the rat brain. Relation to blockade of apomorphine induced hyperactivity and stereotypies. Journal Neural Transmission, 52, 163–173.Google Scholar
Larsson, M., Forssman, A. & Ohman, R. (1983) High performance liquid Chromatograph method for the determination of haloperidol and reduced haloperidol in serum. Current Therapeutic Research, 34, 999–1008.Google Scholar
Mielke, D. H., Gallant, D. M. & Kessler, C. (1977) An evaluation of a unique new antipsychotic agent, sulpiride: Effects on serum prolactin and growth hormone levels. American Journal of Psychiatry, 134, 1371–1385.Google ScholarPubMed
Niskanen, P., Tamminen, T. & Viukari, M. (1975) Sulpiride vs amitriptyline in the treatment of depression. Current Therapeutic Research, 17, 281–284.Google ScholarPubMed
Overall, I. & Gorham, M. (1962) The brief psychiatric rating scale. Psychological Report, 10, 799–812.Google Scholar
Rao, V. A. R., Bailey, J., Mirkin, A. & Coppen, A. (1980) A clinical and pharmadocynamic evaluation of sulpiride. Psychopharmacology, 80, 73–77.Google Scholar
Sarteschi, P., Conti, L. & Cassano, C. B. (1979) Sulpiride in the treatment of psychotic and neurotic syndromes In Sulpiride and other Benzamides (eds. Spano, P. F., Trabucchi, M., Corsini, G. & Gessa, G. L.). Milan: Italian Brain Research Foundation Press.Google Scholar
Tagliamonte, A., Montis de, G., Olianas, M. Vargiu, L., Corsini, G. U. & Gessa, G. L. (1975) Selective increase of brain dopamine synthesis by sulpiride. Journal of Neurochemistry, 24, 707–710.CrossRefGoogle ScholarPubMed
Submit a response

eLetters

No eLetters have been published for this article.